Colon and stomach cancer lynch syndrome or hnpcc


Colon and stomach cancer lynch syndrome or hnpcc

Illness declared in 1992 Testimony confirmed in January 2013

March 1992 – During a colonoscopy, discovery of a liberkünien adenocarcinoma which will require a colectomy of the right colon. The histological report shows vascular emboli, which will lead to chemotherapy for 6 months.

January 1996 – Following an annual check-up, discovery of a stromal type gastric tumor, the surgeon will perform a total gastrectomy. It was a big intervention with very difficult consequences.

October 1996 – A new test detects a sessile polyp that cannot be removed by colonoscopy, so again a subtotal colectomy is performed.

Genetic research was then carried out, confirming a genetic abnormality “Lynch syndrome or HNPCC (Hereditary Non Polyposis Colorectal Cancer)” which predisposes to the development of colonic adenomas in more than 40% of cases.

July 1997 – My ACE markers were on the rise, which means that the cancer process was starting again, and there my surgeon offered me an operation for exploration, which I postpone because I was so weak (55kg). I was already condemned by the medical profession.

A few weeks before, I had learned about the BELJANSKI approach and started taking 9 capsules of Pao pereira 9 capsules of Rauwolfia vomitoria per day. My ACEs therefore decreased and during my next consultation with my surgeon, 3 months later, he concluded that there was no longer any question of operation.

Beljanski treatment: No side effects

I kept this dosage until 2001 and then in reduced doses (4 capsules of Pao pereira and 4 capsules of Rauwolfia vomitoria).

I can tell you then that my body absorbed them without any side effects. Non-toxic, these capsules bring me great comfort in my state of health. I am currently hesitant to make cuts in my intake of these dietary supplements due to my genetic mutation.

For the first time this year, I made a three-month cut with recovery on July 1, 2008 at the rate of 3 capsules of Pao pereira and 3 capsules of Rauwolfia vomitoria per day, my health continuing to be very satisfactory after such problems .

I am scandalized that these formulas are not authorized on the French market, reimbursed by Social Security, and that only a minority of patients have access to them financially.

I express my deep gratitude to Professor BELJANSKI for all his work which has made it possible to develop these valuable formulations.

My wife and I were lucky enough to meet him in 1997 during the picnic in Saintes and we will always remember this exceptional man, accessible and generous.

Thank you also to Pierrette WEIDLICH for having accepted the presidency of CIRIS, an association which remains essential for patients in France and for ensuring its sustainability.